All posts from

Monika
Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer

Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is expected to be the second most deadly cancer by 2040, owing to the high incidence of metastatic disease and limited responses to treatment. Less than half of all patients respond to the primary treatment for PDAC, chemotherapy, and genetic alterations alone cannot explain this. Using shotgun metagenomic sequencing and metabolomic screening, we show that the microbiota-derived tryptophan metabolite indole-3-acetic acid (3-IAA) is enriched in patients who respond to treatment.

read more
Advancing cancer treatment by targeting dysregulated metabolism – A roadmap

Advancing cancer treatment by targeting dysregulated metabolism – A roadmap

Cancer cells adjust metabolic program to their specific energy needs in response to challenging microenvironment, which frequently results in cancer cell “addiction” to certain metabolic pathways. Those “addictions” could be deployed as treatment targets. Metabolic profiling by providing quantitative measure of metabolic processes offers attractive strategy for investigation of not only cancer cells “addictions” but also metabolic switches contributing to treatment resistance.

read more
Happy birthday biocrates

Happy birthday biocrates

This summer, biocrates celebrates 20 years at the forefront of metabolomics. To mark the occasion and take a look back over the highlights of the last two decades, the global team got together in Innsbruck in July.

read more
COVID-19 Utility of animal models

COVID-19 Utility of animal models

The global impact of the COVID-19 pandemic has prompted collaborative research efforts across the world. Thus far, the bulk of these efforts have been geared towards vaccine development and discovery of therapeutic strategies that mitigate disease severity.

read more